Cargando…

Inhibition of the NLRP3 inflammasome by HSP90 inhibitors

Excessive and dysregulated inflammation is known to contribute to disease progression. HSP90 is an intracellular chaperone known to regulate inflammatory processes including the NLRP3 inflammasome and secretion of the pro‐inflammatory cytokine interleukin(IL)‐1β. Here, primarily using an in vitro in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nizami, Sohaib, Arunasalam, Kanisa, Green, Jack, Cook, James, Lawrence, Catherine B., Zarganes‐Tzitzikas, Tryfon, Davis, John B., Di Daniel, Elena, Brough, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730016/ https://www.ncbi.nlm.nih.gov/pubmed/32954500 http://dx.doi.org/10.1111/imm.13267

Ejemplares similares

A phenotypic high-content, high-throughput screen identifies inhibitors of NLRP3 inflammasome activation
por: Nizami, Sohaib, et al.
Publicado: (2021)

Author Correction: A phenotypic high-content, high-throughput screen identifies inhibitors of NLRP3 inflammasome activation
por: Nizami, Sohaib, et al.
Publicado: (2021)

Hsp90 inhibition as a means to inhibit activation of the NLRP3 inflammasome
por: Piippo, Niina, et al.
Publicado: (2018)

Atorvastatin (Lipitor) by MCR
por: Zarganes-Tzitzikas, Tryfon, et al.
Publicado: (2019)

Isoquercitrin Attenuates Steatohepatitis by Inhibition of the Activated NLRP3 Inflammasome through HSP90
por: Ma, Ji, et al.
Publicado: (2023)

Application of Silver Nanoparticles in the Multicomponent Reaction Domain: A Combined Catalytic Reduction Methodology to Efficiently Access Potential Hypertension or Inflammation Inhibitors
por: Iordanidou, Domna, et al.
Publicado: (2018)

Boron-Based Inhibitors of the NLRP3 Inflammasome
por: Baldwin, Alex G., et al.
Publicado: (2017)

MCR Scaffolds Get Hotter with (18)F-Labeling
por: Zarganes-Tzitzikas, Tryfon, et al.
Publicado: (2019)

Late-Stage Copper-Catalyzed Radiofluorination of an Arylboronic Ester Derivative of Atorvastatin
por: S. Clemente, Gonçalo, et al.
Publicado: (2019)

Multicomponent reaction–derived covalent inhibitor space
por: Sutanto, Fandi, et al.
Publicado: (2021)

Echinatin effectively protects against NLRP3 inflammasome–driven diseases by targeting HSP90
por: Xu, Guang, et al.
Publicado: (2021)

Multicomponent Reactions: “Kinderleicht”
por: Neochoritis, Constantinos G., et al.
Publicado: (2020)

Inhibiting the NLRP3 Inflammasome
por: El-Sharkawy, Lina Y., et al.
Publicado: (2020)

LRRC8A is essential for hypotonicity-, but not for DAMP-induced NLRP3 inflammasome activation
por: Green, Jack P, et al.
Publicado: (2020)

Itaconate and fumarate derivatives inhibit priming and activation of the canonical NLRP3 inflammasome in macrophages
por: Hoyle, Christopher, et al.
Publicado: (2022)

Design, Synthesis and Evaluation of Oxazaborine Inhibitors of the NLRP3 Inflammasome
por: Baldwin, Alex G., et al.
Publicado: (2018)

TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells
por: Ranta-aho, Sofia, et al.
Publicado: (2021)

Synthesis of Highly Substituted Imidazole Uracil Containing Molecules via Ugi-4CR and Passerini-3CR
por: Madhavachary, Rudrakshula, et al.
Publicado: (2018)

Bafilomycin A1 enhances NLRP3 inflammasome activation in human monocytes independent of lysosomal acidification
por: Yu, Shi, et al.
Publicado: (2020)

The two pore potassium channel THIK‐1 regulates NLRP3 inflammasome activation
por: Drinkall, Samuel, et al.
Publicado: (2022)

USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation
por: Palazón‐Riquelme, Pablo, et al.
Publicado: (2018)

Discovery and Development Strategies for SARS-CoV-2 NSP3 Macrodomain Inhibitors
por: Schuller, Marion, et al.
Publicado: (2023)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

HSP70 is a negative regulator of NLRP3 inflammasome activation
por: Martine, Pierre, et al.
Publicado: (2019)

Carnosol inhibits inflammasome activation by directly targeting HSP90 to treat inflammasome-mediated diseases
por: Shi, Wei, et al.
Publicado: (2020)

[(18)F]Atorvastatin: synthesis of a potential molecular imaging tool for the assessment of statin-related mechanisms of action
por: Clemente, Gonçalo S., et al.
Publicado: (2020)

Hallmarks of NLRP3 inflammasome activation are observed in organotypic hippocampal slice culture
por: Hoyle, Christopher, et al.
Publicado: (2020)

Nanoscale, automated, high throughput synthesis and screening for the accelerated discovery of protein modifiers
por: Gao, Kai, et al.
Publicado: (2021)

Pharmacological Inhibitors of the NLRP3 Inflammasome
por: Zahid, Ayesha, et al.
Publicado: (2019)

The NLRP3–inflammasome as a sensor of organelle dysfunction
por: Seoane, Paula I., et al.
Publicado: (2020)

HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
por: Kijima, Toshiki, et al.
Publicado: (2018)

Priming Is Dispensable for NLRP3 Inflammasome Activation in Human Monocytes In Vitro
por: Gritsenko, Anna, et al.
Publicado: (2020)

Corrigendum: Priming Is Dispensable for NLRP3 Inflammasome Activation in Human Monocytes In Vitro
por: Gritsenko, Anna, et al.
Publicado: (2021)

NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases
por: Mezzaroma, Eleonora, et al.
Publicado: (2021)

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors
por: Woodford, Mark R., et al.
Publicado: (2016)

Hsp90 Inhibitors Prevent HSV-1 Replication by Directly Targeting UL42-Hsp90 Complex
por: Qin, Shurong, et al.
Publicado: (2022)

Upregulation of TGF-β-induced HSP27 by HSP90 inhibitors in osteoblasts
por: Kuroyanagi, Gen, et al.
Publicado: (2022)

Sphingosine regulates the NLRP3-inflammasome and IL-1β release from macrophages
por: Luheshi, Nadia M, et al.
Publicado: (2012)

Characterisation of C101248: A novel selective THIK-1 channel inhibitor for the modulation of microglial NLRP3-inflammasome
por: Ossola, Bernardino, et al.
Publicado: (2023)

Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists
por: Neochoritis, Constantinos G, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kvsua46fnr6sa4vbh4kdr6qafl